Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
DVAX Stock Summary
Top 10 Correlated ETFs
DVAX
In the News
Dynavax Technologies: Still A Believer
Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax's stock has been trading at the lower end of its range, but with positive prospects and a strong balance sheet, it presents a solid long-term investment opportunity.
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Dynavax Technologies (DVAX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.45 per share a year ago.
Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why
Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P.
Dynavax Technologies: Still A Solid Pick For 2024
Today, we take another look at Dynavax Technologies Corporation, which experienced a boost in revenue from the Covid pandemic, but this has now nearly completely diminished. However, the company's core asset is the HEPLISAV-B, a vaccine for Hepatitis B, which has gained market share and achieved high compliance rates. Third quarter results showed strong performance for HEPLISAV-B, leading to an increase in sales guidance for 2023. Analysts also expect a rebound in earnings and sales in 2024.
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m.
Is Dynavax Technologies (DVAX) Outperforming Other Medical Stocks This Year?
Here is how Dynavax Technologies (DVAX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
DVAX Financial details
DVAX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.49 | 0.46 | 3.3 | 7.12 | 1.8 | |
Net income per share | -2.1 | -0.91 | 0.58 | 2.89 | -0.05 | |
Operating cash flow per share | -1.68 | -0.92 | 2.52 | 0.62 | 0.78 | |
Free cash flow per share | -2.09 | -1.03 | 2.45 | 0.55 | 0.75 | |
Cash per share | 2.1 | 1.64 | 4.1 | 6.15 | 5.77 | |
Book value per share | 0.12 | 0.58 | 1.67 | 5.72 | 4.83 | |
Tangible book value per share | 0.05 | 0.56 | 1.66 | 5.7 | 4.82 | |
Share holders equity per share | 0.12 | 0.58 | 1.67 | 5.72 | 4.83 | |
Interest debt per share | 3.28 | 2.35 | 2.02 | 2.61 | 2.05 | |
Market cap | 411.98M | 448.35M | 1.87B | 1.08B | 1.8B | |
Enterprise value | 588.54M | 634.12M | 1.69B | 1.14B | 1.91B | |
P/E ratio | -2.72 | -4.89 | 24.39 | 3.68 | -281.69 | |
Price to sales ratio | 11.7 | 9.63 | 4.26 | 1.49 | 7.75 | |
POCF ratio | -3.4 | -4.86 | 5.58 | 17.22 | 17.9 | |
PFCF ratio | -2.73 | -4.34 | 5.74 | 19.43 | 18.66 | |
P/B Ratio | 49.7 | 7.64 | 8.42 | 1.86 | 2.89 | |
PTB ratio | 49.7 | 7.64 | 8.42 | 1.86 | 2.89 | |
EV to sales | 16.71 | 13.62 | 3.85 | 1.57 | 8.21 | |
Enterprise value over EBITDA | -5.13 | -9.44 | 11.9 | 3.81 | 90.87 | |
EV to operating cash flow | -4.85 | -6.87 | 5.04 | 18.11 | 18.96 | |
EV to free cash flow | -3.91 | -6.14 | 5.19 | 20.44 | 19.76 | |
Earnings yield | -0.37 | -0.2 | 0.04 | 0.27 | 0 | |
Free cash flow yield | -0.37 | -0.23 | 0.17 | 0.05 | 0.05 | |
Debt to equity | 26.48 | 3.71 | 1.16 | 0.44 | 0.41 | |
Debt to assets | 0.79 | 0.62 | 0.25 | 0.26 | 0.26 | |
Net debt to EBITDA | -1.54 | -2.77 | -1.26 | 0.19 | 5.08 | |
Current ratio | 3.63 | 2.95 | 1.09 | 4.56 | 13.81 | |
Interest coverage | -7.16 | -3.95 | 12.03 | 42.12 | -5.48 | |
Income quality | 0.79 | 1.23 | 4.37 | 0.21 | -15.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 1.7 | 0.23 | 0.18 | 0.66 | |
Research and developement to revenue | 1.77 | 0.61 | 0.07 | 0.06 | 0.24 | |
Intangibles to total assets | 0.02 | 0.01 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.24 | 0.12 | -0.03 | -0.11 | -0.04 | |
Capex to revenue | -0.83 | -0.24 | -0.02 | -0.01 | -0.02 | |
Capex to depreciation | -1.37 | -1.19 | -1.35 | -1.07 | -0.56 | |
Stock based compensation to revenue | 0.72 | 0.29 | 0.05 | 0.05 | 0.18 | |
Graham number | 2.33 | 3.46 | 4.66 | 19.29 | 2.32 | |
ROIC | -0.45 | -0.29 | 0.26 | 0.32 | -0.06 | |
Return on tangible assets | -0.55 | -0.26 | 0.07 | 0.3 | -0.01 | |
Graham Net | -1.28 | -0.8 | -1.06 | 3.55 | 3.32 | |
Working capital | 139.34M | 151.31M | 50.88M | 533.77M | 796.93M | |
Tangible asset value | 3.71M | 56.4M | 220.25M | 579.01M | 620.01M | |
Net current asset value | -78.39M | -65.85M | -209.59M | 279M | 484.1M | |
Invested capital | 26.48 | 3.71 | 1.16 | 0.44 | 0.41 | |
Average receivables | 6.3M | 15.77M | 77.24M | 139.67M | 96.02M | |
Average payables | 7.28M | 6.3M | 2.96M | 2.91M | 4.23M | |
Average inventory | 30.18M | 52.51M | 62.51M | 60.39M | 56.37M | |
Days sales outstanding | 92.09 | 177.68 | 109.49 | 74.5 | 69.98 | |
Days payables outstanding | 174.66 | 86.91 | 5.47 | 4.47 | 38.16 | |
Days of inventory on hand | 778.08 | 1.67K | 128.98 | 82.77 | 387.72 | |
Receivables turnover | 3.96 | 2.05 | 3.33 | 4.9 | 5.22 | |
Payables turnover | 2.09 | 4.2 | 66.76 | 81.64 | 9.56 | |
Inventory turnover | 0.47 | 0.22 | 2.83 | 4.41 | 0.94 | |
ROE | -18.26 | -1.56 | 0.34 | 0.5 | -0.01 | |
Capex per share | -0.41 | -0.11 | -0.07 | -0.07 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.22 | 0.37 | 0.4 | 0.45 | 431.87 | |
Net income per share | 0.45 | -0.19 | 0.02 | 0.09 | 1.7 | |
Operating cash flow per share | 0.23 | 0.22 | 0.18 | 0.2 | 106.93 | |
Free cash flow per share | 0.22 | 0.21 | 0.18 | 0.2 | 93.55 | |
Cash per share | 4.12 | 5.1 | 4.48 | 4.67 | 5.77K | |
Book value per share | 3.83 | 4.41 | 3.79 | 3.92 | 4.83K | |
Tangible book value per share | 3.82 | 4.39 | 3.78 | 3.91 | 4.82K | |
Share holders equity per share | 3.83 | 4.41 | 3.79 | 3.92 | 4.83K | |
Interest debt per share | 1.71 | 2.03 | 1.7 | 1.68 | 2.02K | |
Market cap | 1.61B | 1.25B | 1.97B | 2.28B | 1.8M | |
Enterprise value | 1.67B | 1.33B | 2B | 2.38B | 108.43M | |
P/E ratio | 5.96 | -12.89 | 143.23 | 39.84 | 2.05 | |
Price to sales ratio | 8.75 | 26.74 | 32.63 | 32.76 | 0.03 | |
POCF ratio | 46.19 | 45.43 | 70.09 | 73.16 | 0.13 | |
PFCF ratio | 48.39 | 47.64 | 72.02 | 73.99 | 0.15 | |
P/B Ratio | 2.78 | 2.23 | 3.41 | 3.76 | 0 | |
PTB ratio | 2.78 | 2.23 | 3.41 | 3.76 | 0 | |
EV to sales | 9.05 | 28.44 | 33.14 | 34.18 | 1.95 | |
Enterprise value over EBITDA | 23.98 | -137.34 | 269.49 | 160.14 | 19.77 | |
EV to operating cash flow | 47.8 | 48.31 | 71.19 | 76.33 | 7.88 | |
EV to free cash flow | 50.07 | 50.67 | 73.15 | 77.19 | 9 | |
Earnings yield | 0.04 | -0.02 | 0 | 0.01 | 0.12 | |
Free cash flow yield | 0.02 | 0.02 | 0.01 | 0.01 | 6.69 | |
Debt to equity | 0.44 | 0.46 | 0.45 | 0.43 | 0.41 | |
Debt to assets | 0.26 | 0.27 | 0.28 | 0.26 | 0.26 | |
Net debt to EBITDA | 0.8 | -8.2 | 4.18 | 6.64 | 19.44 | |
Current ratio | 4.56 | 9.07 | 17.78 | 15.4 | 13.81 | |
Interest coverage | 37.49 | -10.64 | -2.42 | 3.03 | -3.36 | |
Income quality | 0.52 | -1.14 | 8.17 | 2.18 | 62.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.17 | 0.78 | 0.62 | 0.55 | 0.74 | |
Research and developement to revenue | 0.07 | 0.29 | 0.22 | 0.2 | 0.25 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.05 | -0.05 | -0.03 | -0.01 | -0.13 | |
Capex to revenue | -0.01 | -0.03 | -0.01 | 0 | -0.03 | |
Capex to depreciation | -1.1 | -0.78 | -0.42 | -0.19 | -0.88 | |
Stock based compensation to revenue | 0.05 | 0.21 | 0.18 | 0.15 | 0.2 | |
Graham number | 6.2 | 4.34 | 1.39 | 2.86 | 430.07 | |
ROIC | 0.07 | -0.02 | 0 | 0.01 | 0 | |
Return on tangible assets | 0.07 | -0.03 | 0 | 0.01 | 0 | |
Graham Net | 2.37 | 2.74 | 2.52 | 2.67 | 3.32K | |
Working capital | 533.77M | 738.63M | 752.6M | 781.4M | 796.93M | |
Tangible asset value | 579.01M | 561.69M | 575.17M | 602.94M | 620.01M | |
Net current asset value | 279M | 423.95M | 438.23M | 467.65M | 484.1M | |
Invested capital | 0.44 | 0.46 | 0.45 | 0.43 | 0.41 | |
Average receivables | 139.32M | 124.63M | 73.55M | 46.11M | 45.7M | |
Average payables | 3.13M | 5.25M | 5.27M | 3.18M | 4.18M | |
Average inventory | 81.03M | 58.57M | 55.39M | 51.25M | 51.35M | |
Days sales outstanding | 71.96 | 195.13 | 67.75 | 60.68 | 72.09 | |
Days payables outstanding | 3.73 | 44.63 | 21.58 | 21.23 | 54.33 | |
Days of inventory on hand | 69.04 | 352.93 | 352.95 | 336.16 | 551.97 | |
Receivables turnover | 1.25 | 0.46 | 1.33 | 1.48 | 1.25 | |
Payables turnover | 24.13 | 2.02 | 4.17 | 4.24 | 1.66 | |
Inventory turnover | 1.3 | 0.26 | 0.25 | 0.27 | 0.16 | |
ROE | 0.12 | -0.04 | 0.01 | 0.02 | 0 | |
Capex per share | -0.01 | -0.01 | 0 | 0 | -13.38 |
DVAX Frequently Asked Questions
What is Dynavax Technologies Corporation stock symbol ?
Dynavax Technologies Corporation is a US stock , located in Emeryville of Ca and trading under the symbol DVAX
What is Dynavax Technologies Corporation stock quote today ?
Dynavax Technologies Corporation stock price is $12.41 today.
Is Dynavax Technologies Corporation stock public?
Yes, Dynavax Technologies Corporation is a publicly traded company.